1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sophiris Will Start Phase III For Topsalysin In Prostate Cancer Despite Mixed Data Package

 
• By Joseph Haas

Emphasizing solid results for the first administration of topsalysin in patients with localized prostate cancer, the firm is sticking with Phase III plans for one dose despite final Phase IIb data showing no clinical benefit from a second dose. Sophiris’ share price tumbled on the news.

Cancer cells

Sophiris Bio Inc. will forge ahead with plans for a Phase III study of its prostate cancer candidate topsalysin despite final data from a Phase IIb study showing that a second administration of the drug did not provide a clinical benefit in patients who were partial responders to a first dose. The San Diego biotech hopes to meet with US and EU regulators in early 2019 to draw up a Phase III study based on one-time administration of the drug, execs said during an investor call Dec. 17.

Sophiris’ stock finished the trading day down 40%, to $1.23 per share, the latest swing in an up-and-down 2018 for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?

 
• By Alaric DeArment

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer

 
• By Alaric DeArment

The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.

Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact

 
• By Kevin Grogan

Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.

More from Therapy Areas

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.

AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer

 
• By Alaric DeArment

The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.

Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’

 
• By Manas Mishra

Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.